COX-2 inhibitors and the cardiovascular system: Is there a class effect?

British Journal of Cardiology

Volumn 12, Issue 5, 2005, Pages 387-391

  Bakr, Mohamed ^a   Waller, Derek G ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Blood pressure; Cardiovascular events; COX 2 selective inhibitors (coxibs); Myocardial infarction; Non steroidal anti inflammatory drugs (NSAIDs); Prostaglandins

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IBUPROFEN; LUMIRACOXIB; MELOXICAM; NABUMETONE; NAPROXEN; PROSTAGLANDIN; ROFECOXIB; VALDECOXIB;

ARTHRITIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE EXACERBATION; DRUG MECHANISM; EDEMA; EVIDENCE BASED MEDICINE; GASTROINTESTINAL TOXICITY; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; ISCHEMIA; KIDNEY DYSFUNCTION; REVIEW; RISK ASSESSMENT; SODIUM RETENTION; STROKE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; VASODILATATION; WATER RETENTION;

EID: 27744475432     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Schachter M. COX-2 inhibitors and cardiovascular risk. Br J Cardiol 2003;10:288-91.
2. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
3. Antiplatelet Trialist's Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 2002;324:71-86.
4. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 2000;284:1247-55.
5. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
6. Konstam MA, Weir MR, Reicin A et al. Cardiovascular thrombotic events in controlled clinical trials of rofecoxib. Circulation 2001;104:2280-8.
7. Layton D, Hughes K, Harris S, Shakir SA et al. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data. Rheumatology (Oxford) 2003;42:1354-640. http://rheumatology.oupjournals.org
8. Layton D, Heeley E, Hughes K, Shakir SA et al. Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (Oxford) 2003;42: 1342-530. http://rheumatologyoupjournals.org
9. Whelton A. Rofecoxib increases cardiovascular events in arthritis patients but celecoxib and nonspecific nonsteroidal anti-inflammatory drugs do not: results from a large New England healthcare claims database. 53rd American College of Cardiology Annual Scientific Session, 7th-10th March 2004, New Orleans, US. Abstract 838-2.
10. Ray WA, Stein CM, Daugherty JR et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360:1071-3.
11. Solomon DH, Schneeweiss S, Glynn RJ et al. Relationship between selective cyclooxygenase inhibitors and acute myocardial infarction in older adults. Circulation 2004;109:2068-73.
12. Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
13. Solomon SD, McMurray JJV, Pfeiffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal cancer prevention. N Engl J Med 2005;352:1071-80.
14. Shaya FT, Blume SW, Blanchette CM et al. Selective cyclooxygenase inhibition and cardiovascular effects. Arch Intern Med 2005;165:181-6.
15. Curtis S, Mukhopadhyay S, Ramey D et al. Etoricoxib cardiovascular safety summary. American Heart Association Scientific Sessions 2003, 9th-12th November 2003, Orlando, US. Abstract 1758.
16. Farkouh ME, Kirshner H, Harrington RA et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomized controlled trial. Lancet 2004;364:675-84.
17. Ray WA, Griffin MR, Stein CM. Cardiovascular toxicity of valdecoxib. N Engl J Med 2004;351:2767.
18. Nussmeier NA, Whelton AA, Brown MT et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-91.
19. Whelton A, Forte JG, Puma JA et al. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001;8:85-95.
20. Whelton A, White WB, Bello AE et al. Effects of celecoxib and rofecoxib on blood pressure and oedema in patients >65 years with systemic hypertension and osteoarthritis. Am J Cardiol 2002;90:959-63.
21. Zhao SZ, Reynolds MW, Lejkowith J et al. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organisation/Uppsala Monitoring centre safety database. Clin Ther 2001;23:1478-91.
22. Mamdani M, Juurlink DN, Lee DS et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004;363:1751-6.
23. Johnson AG, Nguyen TV, Day RO. Do non-steroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121:289-300.
24. Gurwitz JH, Avorn J, Bohn RL, Glynn RJ, Monane M, Mogun H. Initiation of antihypertensive treatment during non-steroidal anti-inflammatory drug therapy. JAMA 1994;272:781-6.
25. Langman MJS, Eichler H-G, Mavros P et al. Initiation of antihypertensive therapy among new users of cyclooxygenase-2-selective and non-selective NSAIDs. Int J Clin Pharm Ther 2004;42:260-6.
26. Solomon DH, Schneeweiss S, Levin R et al. Relationship between COX-2 specific inhibitors and hypertension. Hypertension 2004;44:140-5.
27. Wolfe F, Zhao S, Reynolds M et al. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and non-selective non-steroidal anti-inflammatory drugs (NSAID) and non-users of NSAID receiving ordinary clinical care. J Rheumatol 2004;31:1143-51.
28. Palmer R, Weiss R, Zusman RM et al. Effects of nabumetone, celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors. Am J Hypertens 2003;16: 135-9.
29. White WB, Kent J, Taylor A et al. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002;39:929-34.
30. Izhar M, Alausa T, Folker A et al. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and Hispanics. Hypertension 2004;43:573-7.
31. Reitblat T, Zamir D, Estis L et al. The different patterns of blood pressure elevation by rofecoxib and nabumetone. J Hum Hypertens 2002;16: 431-4.
32. Sowers JR, White WB, Pitt B et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis and type 2 diabetes mellitus. Arch Intern Med 2005;165:161-8.
33. Aw T-J, Haas SJ, Liew D et al. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165:1-7.